Form 4: Labcorp Executive Sells Shares Under Pre-Arranged Trading Plan

Labcorp Holdings Inc. Executive Vice President Brian J. Caveney reported the sale of 2,000 shares of common stock at $247 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Brian J. Caveney, EVP, President of ED, CMO & CSO of Labcorp Holdings Inc. (LH), reported a transaction on June 3, 2025.
• The transaction involved the disposition (sale) of 2,000 shares of Labcorp common stock.
• Each share was sold at a price of $247, totaling $494,000.
• Following this transaction, Mr. Caveney beneficially owns 30,066.6573 shares of common stock directly.
• The sale was conducted pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine insider sale conducted under a pre-arranged 10b5-1 plan, which typically indicates a planned diversification or liquidity event rather than a negative signal about the company's prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider stock transaction and does not provide broader industry context or trends. It reflects an individual executive's portfolio management rather than a strategic company-level move within the healthcare diagnostics industry.

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan is generally not considered a significant signal for shareholders, as it's a pre-planned event rather than a reaction to new information. The impact on share price is likely minimal given the transaction size relative to the company's market capitalization.

Key Dates

Keywords

Labcorp Holdings Inc., LH, Insider Trading, Form 4, Stock Sale, Executive Compensation, Brian J. Caveney, Rule 10b5-1 Plan